Transcatheter Aortic Valve Implantation (TAVI) Market

Market Overview:

The global transcatheter aortic valve implantation (TAVI) market size reached USD 7.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 17.4 Billion by 2033, exhibiting a growth rate (CAGR) of 10.12% during 2025-2033. The increasing prevalence of coronary artery disease, the rising adoption of minimally invasive therapies, and the expanding geriatric population represent some of the key factors driving the market.

Transcatheter Aortic Valve Implantation (TAVI) refers to a minimally invasive surgical procedure used to treat aortic stenosis, a heart condition in which the aortic valve narrows, resulting in reduced blood flow from the heart to the rest of the body. During the procedure, a small incision is made in the patient's groin or chest. A catheter is inserted and guided through the femoral artery or the aorta to the narrowed aortic valve. An artificial valve made of biological material, such as animal tissue or synthetic materials, is deployed through the catheter and positioned inside the narrowed valve, which expands to replace the old valve, allowing blood to flow freely from the heart. TAVI can be performed under local anesthesia. Compared to traditional surgery, it has a shorter recovery time and a lower risk of complications and can be performed on patients who are too ill or frail to undergo open-heart surgery.

Transcatheter Aortic Valve Implantation (TAVI) Market Trends:

The growing number of patients suffering from heart failure, hypertension, coronary artery disease, and cardiovascular diseases (CVDs), particularly aortic stenosis, is primarily driving the transcatheter aortic valve implantation (TAVI) market growth. Besides this, the shifting consumer preference for minimally invasive surgery (MIS) over conventional open-heart surgery due to its advantages, such as reduced hospital stay, shorter recovery time, improved outcomes, and lower overall healthcare spending, is creating a positive outlook for the market. Moreover, the escalating consumer awareness about aortic valve disease and available treatment options leading to early diagnosis and timely treatment is contributing to the market growth. In addition to this, the extensive funding in research and development (R&D) initiatives and ongoing technological advancements in the TAVI procedure, such as the development of bioprosthetic valves, self-expanding valves, and other innovative devices, are strengthening the market growth. Furthermore, the bolstering growth of the healthcare industry, the increasing number of clinical trials, continuous product innovations, the expanding geriatric population, and favorable reimbursement policies are presenting remunerative growth opportunities for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global transcatheter aortic valve implantation (TAVI) market, along with forecasts at the global, regional, and country levels from 2025-2033. Our report has categorized the market based on procedure and end user.

Procedure Insights:

• Transfemoral Procedure
• Transapical Implantation
• Transaortic Implantation
   

The report has provided a detailed breakup and analysis of the transcatheter aortic valve implantation (TAVI) market based on the procedure. This includes the transfemoral procedure, transapical implantation, and transaortic implantation. According to the report, transfemoral procedure represented the largest segment.

End User Insights:

• Hospitals
• Diagnostic Labs
• Ambulatory Surgical Centers
• Clinics
• Others
   

A detailed breakup and analysis of the transcatheter aortic valve implantation (TAVI) market based on the end user has also been provided in the report. This includes hospitals, diagnostic labs, ambulatory surgical centers, clinics, and others. According to the report, hospitals accounted for the largest market share.

Regional Insights:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for transcatheter aortic valve implantation (TAVI). Some of the factors driving the North America transcatheter aortic valve implantation (TAVI) market included the expanding prevalence of cardiovascular diseases, the rising adoption of minimally invasive therapies, and ongoing technological advancements.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global transcatheter aortic valve implantation (TAVI) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Boston Scientific Corporation, Edwards Lifesciences Corporation, JC Medical Inc. (Genesis Medtech International Private Limited), Medtronic plc, Meril Life Sciences Pvt. Ltd., NVT AG (Biosensors International Group), Venus Medtech (Hangzhou) Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Report Scope:

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the transcatheter aortic valve implantation (TAVI) market from 2019-2033.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global transcatheter aortic valve implantation (TAVI) market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the transcatheter aortic valve implantation (TAVI) industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.